{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Thrombosis",
    "query": {
      "condition": "Cancer Thrombosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 99,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Thrombosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T05:14:50.633Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04979780",
      "title": "Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Treatment of Venous Thromboembolism in Cancer Patients",
        "Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Low molecular weight heparin (LMWH)",
          "type": "DRUG"
        },
        {
          "name": "Direct Oral Anticoagulants (DOAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3708,
      "start_date": "2021-07-20",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Connecticut",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979780"
    },
    {
      "nct_id": "NCT01853202",
      "title": "EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer Thrombosis"
      ],
      "interventions": [
        {
          "name": "Supervised aerobic exercise training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-12-04",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853202"
    },
    {
      "nct_id": "NCT05171049",
      "title": "A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Deep Venous Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Abelacimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Anthos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1150,
      "start_date": "2022-05-05",
      "completion_date": "2026-02-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 23,
      "location_summary": "Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05171049"
    },
    {
      "nct_id": "NCT04385160",
      "title": "Myeloproliferative Neoplasms (MPN) and COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myeloproliferative Neoplasm",
        "COVID"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 552,
      "start_date": "2020-05-13",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04385160"
    },
    {
      "nct_id": "NCT05319015",
      "title": "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Neoadjuvant Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection",
          "type": "PROCEDURE"
        },
        {
          "name": "Adjuvant Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-01-06",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05319015"
    },
    {
      "nct_id": "NCT07292376",
      "title": "Implementing VTE Prevention in Ambulatory Cancer Care",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Clinical program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2025-10-01",
      "completion_date": "2026-07-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07292376"
    },
    {
      "nct_id": "NCT03045406",
      "title": "Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Dalteparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fadoi Foundation, Italy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1170,
      "start_date": "2017-04-13",
      "completion_date": "2019-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03045406"
    },
    {
      "nct_id": "NCT02473536",
      "title": "Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Stereotactic ablative radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-06",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473536"
    },
    {
      "nct_id": "NCT01325558",
      "title": "A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Malignant Neoplasm",
        "Malignant Solid Tumour"
      ],
      "interventions": [
        {
          "name": "ALT-836 in combination with gemcitabine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-05",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325558"
    },
    {
      "nct_id": "NCT00381888",
      "title": "Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Thromboembolism",
        "Vaginal Cancer",
        "Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "fondaparinux sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 44,
      "start_date": "2007-01",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-07-24T05:14:50.633Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Upland, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Upland",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381888"
    }
  ]
}